SRTS
Sensus Healthcare, Inc.
Overview
Sensus Healthcare manufactures and sells superficial radiation therapy (SRT) devices for treating non-melanoma skin cancer and keloid scars. The company's product line includes the SRT-100, SRT-100+, and SRT-100 Vision systems, which use low-energy X-ray technology as a non-invasive alternative to surgery.
Sensus Healthcare, Inc is a Healthcare company operating in Medical Devices with a $45.6M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-076 Q&A exchanges
- Q4 FY2025Earnings2026-02-128 Q&A exchanges
- Q3 FY2025Earnings2025-11-0611 Q&A exchanges
- Q2 FY2025Earnings2025-08-0813 Q&A exchanges
- Q1 FY2025Earnings2025-05-1524 Q&A exchanges
- Q4 FY2024Earnings2025-02-0511 Q&A exchanges
- Q3 FY2024Earnings2024-11-1415 Q&A exchanges
- Q2 FY2024Earnings2024-08-1117 Q&A exchanges
- Q1 FY2024Earnings2024-05-0910 Q&A exchanges
- Q4 FY2023Earnings2024-02-0825 Q&A exchanges
- Q3 FY2023Earnings2023-11-0915 Q&A exchanges
- Q2 FY2023Earnings2023-08-0620 Q&A exchanges
- Q1 FY2023Earnings2023-05-0332 Q&A exchanges
- Q4 FY2022Earnings2023-02-0920 Q&A exchanges
- Q3 FY2022Earnings2022-11-0631 Q&A exchanges
- Q2 FY2022Earnings2022-08-0717 Q&A exchanges
- Q1 FY2022Earnings2022-05-0810 Q&A exchanges
- Q4 FY2021Earnings2022-02-1021 Q&A exchanges
- Q3 FY2021Earnings2021-11-0726 Q&A exchanges
- Q2 FY2021Earnings2021-05-0610 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.10—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.10 | — | — | — | — | EODHD |
Source: EODHD. SRTS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks SRTS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 9/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.10 | $2.12 | -0.8% | -0.7% | +0.3% |
| Q4 FY2026 | $2.10 | $2.20 | -4.7% | -7.9% | -9.8% |
| Q3 FY2026 | $2.30 | $2.37 | -2.9% | +2.1% | +2.9% |
| Q2 FY2026 | $2.26 | $2.41 | -6.1% | -7.4% | -7.2% |
| Q1 FY2025 | $2.16 | $2.20 | -1.9% | -2.9% | -0.4% |
| Q4 FY2025 | $2.19 | $2.22 | -1.3% | -7.2% | -5.5% |
| Q3 FY2025 | $2.12 | $2.28 | -7.2% | -8.1% | -9.7% |
| Q2 FY2025 | $2.23 | $2.35 | -4.9% | -7.9% | -9.7% |
| Q1 FY2024 | $2.28 | $2.28 | -0.2% | -1.9% | -2.8% |
| Q4 FY2024 | $2.24 | $2.32 | -3.6% | -1.2% | 0.0% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Maintained2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph C SardanoCEO3 yr 1 mo20 callsCurrentSample
CEO since 2023 • 6/12 beats (50%) • guidance suspended Q1 FY2026
- Michael SardanoPresident2 yr 10 mo15 callsCurrentSample
PRESIDENT since 2023 • 4/12 beats (33%) • last guidance cut Q2 FY2026
- Carlton ChowChief Technology Officer1 yr 1 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Javier RampollaCFO2 yr 7 mo20 callsFormerSample
CFO since 2022 • 12/16 beats (75%) • guidance suspended Q1 FY2026
- Magdalena MartinezCOO11 mono recorded callsFormerSample
COO since 2023 • 7/12 beats (58%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SRTS.
$ curl https://api.spokenalpha.com/v1/companies/SRTSFAQ
Frequently asked about SRTS
Where can I find Sensus Healthcare, Inc.'s (SRTS) earnings call transcripts?
Spoken Alpha indexes SRTS's earnings call transcripts at https://spokenalpha.com/companies/SRTS. Each call links to attributed speakers and parsed analyst Q&A. Sensus Healthcare, Inc.'s own investor relations page is at https://sensushealthcare.com/investors/.
When was Sensus Healthcare, Inc.'s most recent earnings call?
Sensus Healthcare, Inc. (SRTS) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is SRTS in?
Sensus Healthcare, Inc. (SRTS) operates in the Healthcare sector (Medical Devices industry).